Abstract:Over the past few decades, substantial evidence has convincingly revealed the existence of cancer stem cells (CSCs) as a minor subpopulation in cancers, contributing to an aberrantly high degree of cellular heterogeneity within the tumor. CSCs are functionally defined by their abilities of self-renewal and differentiation, often in response to cues from their microenvironment. Biological phenotypes of CSCs are regulated by the integrated transcriptional, post-transcriptional, metabolic, and epigenetic regulatory networks. CSCs contribute to tumor progression, therapeutic resistance, and disease recurrence through their sustained proliferation, invasion into normal tissue, promotion of angiogenesis, evasion of the immune system, and resistance to conventional anticancer therapies. Therefore, elucidation of the molecular mechanisms that drive cancer stem cell maintenance, plasticity, and therapeutic resistance will enhance our ability to improve the effectiveness of targeted therapies for CSCs. In this review, we highlight the key features and mechanisms that regulate CSC function in tumor initiation, progression, and therapy resistance. We discuss factors for CSC therapeutic resistance, such as quiescence, induction of epithelial-to-mesenchymal transition (EMT), and resistance to DNA damage-induced cell death. We evaluate therapeutic approaches for eliminating therapy-resistant CSC subpopulations, including anticancer drugs that target key CSC signaling pathways and cell surface markers, viral therapies, the awakening of quiescent CSCs, and immunotherapy. We also assess the impact of new technologies, such as single-cell sequencing and CRISPR-Cas9 screening, on the investigation of the biological properties of CSCs. Moreover, challenges remain to be addressed in the coming years, including experimental approaches for investigating CSCs and obstacles in therapeutic targeting of CSCs.

Targeting Cancer Stem Cell Plasticity in Triple-Negative Breast Cancer.

Regulation of cancer stem cells in triple negative breast cancer

Exploring the interplay between triple‐negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies

Human Primary Breast Cancer Stem Cells Are Characterized by Epithelial-Mesenchymal Plasticity

CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs

Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC

Therapeutic vulnerabilities in triple negative breast cancer: Stem-like traits explored within molecular classification

Targeted Cancer Stem Cell Therapeutics: An Update

Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer

Breast cancer stem cells: current advances and clinical implications.

Targeting Cancer Stem Cells and Their Niche: Perspectives for Future Therapeutic Targets and Strategies

Targeting cancer stem cell pathways for cancer therapy

Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment

Role, Molecular Mechanism and the Potential Target of Breast Cancer Stem Cells in Breast Cancer Development

Targeting cancer stem cells in cancer therapy

Advance in Metabolism and Target Therapy in Breast Cancer Stem Cells

Cancer stem cells: advances in knowledge and implications for cancer therapy

Cancer Stem Cell for Tumor Therapy

Navigating the therapeutic landscape for breast cancer: targeting breast cancer stem cells

Stem cell programs in cancer initiation, progression, and therapy resistance

FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters